2067 results about "Blood plasma" patented technology

The invention relates to the technical field of image recognition, and discloses a carotid plaque stability and stroke risk prediction system fusing multiple modes, and the system comprises a data collection and fusion module, a feature extraction and association module, a risk assessment and layering module, an intervention decision module, and a report generation and feedback module. When carotid plaque stability and cerebral apoplexy risk prediction is carried out, plasma proteomics, radiomics and clinical data are synergistically integrated by establishing a multi-modal data fusion analysis framework, so that the limitation that a traditional method depends on a single data source is overcome; the plaque risk can be evaluated from multiple dimensions of biological activity and morphological features, the comprehensiveness and accuracy of risk prediction are improved, a more reliable diagnosis basis is provided for clinic, interaction and sensitivity influence among different modal features can be adaptively quantified by introducing dynamic feature correlation modeling and a real-time weight calibration mechanism, and the risk prediction accuracy is improved. And objectivity and consistency of risk assessment results are ensured.

The invention discloses a block chain-based blood full-process traceability tracking and safety management system and method, and relates to the technical field of blood management, and the method comprises the steps: distributing an encrypted digital identifier with a timestamp for each blood unit; collecting physical characteristic data of the blood storage environment in real time; dynamically adjusting the state mark of the blood product based on a preset plasma quality evaluation model; a threshold signature technology is adopted to ensure that multiple medical institutions complete blood information verification and sharing on the premise of protecting privacy; when it is monitored that the blood environment parameters exceed a safety threshold value, graded early warning is generated, and an emergency processing flow is started; and establishing a blood circulation whole process auditing tracking system. The system has the advantages that the blood whole-process traceability system based on the block chain is constructed, transparent credible management of the whole life cycle of blood products from collection to use is achieved, the trust and privacy protection problem in multi-mechanism cooperation is solved, and the blood safety management level and the emergency processing efficiency are comprehensively improved.

The invention relates to a breast cancer plasma transporter miRNA marker and application thereof, and belongs to the technical field of biological detection. In the prior art, biomarkers for breast cancer liquid biopsy have the problems of low content, high heterogeneity, insufficient time resolution and the like, so that the detection reliability is limited. According to the invention, a specific miRNA (micro Ribonucleic Acid) marker (including one or more of let-7d-5p, miR-103a-3p and miR-22-3p) of the plasma transporter is provided. The marker can be used for preparing a breast cancer detection reagent or kit. Clinical verifications show that the miRNAs are remarkably and highly expressed in plasma migrators of breast cancer patients, the AUC value reaches 0.763-0.808, the sensitivity is 66.7%-86.7%, the specificity is 66.7%-88.3%, the miRNAs have the advantages of high signal-to-noise ratio and dynamic monitoring, and the accuracy and practicability of breast cancer detection are remarkably improved.

The present disclosure, in some aspects, provides one or more biomarkers (e.g., plasma biomarkers or circulating biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., plasma biomarkers or circulating biomarkers) described herein is regulated by DUX4. Methods (e.g., non-invasive methods) of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided. The present disclosure, in other aspects, provides one or more biomarkers (e.g., transcriptome biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., transcriptome biomarkers) described herein is regulated by DUX4. Methods of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided.

The utility model provides a detachable combined type plasma filtering card shell, which comprises a card shell, the card shell comprises an upper cover and a bottom shell clamped with the upper cover, the bottom shell is internally provided with a test paper card slot, and the upper cover is provided with a first sample adding hole facing the test paper card slot; the plasma separator is clamped on the upper cover, and the plasma separator comprises a supporting plate, a liquid storage cavity and a second sample adding hole, and the liquid storage cavity and the second sample adding hole are formed in the supporting plate. According to the detachable combined type plasma filtering clamping shell provided by the utility model, the plasma separator is clamped on the clamping shell, whole blood is added into the second sample adding hole, and then the pressurizing cover is bent to block the second sample adding hole, so that the filtering speed of the whole blood on the filter membrane is accelerated; the filtered plasma flows into the first sample adding hole from the liquid storage cavity to react with the test paper strip on the test paper clamping groove, so that the detection accuracy is improved, and further, the plasma separator and the clamping shell can be separated and independently used.

The invention discloses an esophageal adenocarcinoma plasma circulation microbial marker combination, a reagent, a kit, a risk prediction model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The esophageal adenocarcinoma plasma circulating microbial marker combination disclosed by the invention comprises enterobacteriaceae, cilia, prevotella, ackermania, lactobacillus fermentum and streptococcus. When the esophageal adenocarcinoma plasma circulating microbial marker combination is used for verifying esophageal adenocarcinoma patients and healthy controls, the AUC is 0.952, the sensitivity is 100%, the specificity is 80.00%, the accuracy is 91.43%, the positive predictive value is 86.96%, and the negative predictive value is 100%; the esophageal adenocarcinoma plasma circulating microbial marker combination can effectively distinguish esophageal adenocarcinoma patients from healthy people, is suitable for early screening of esophageal adenocarcinoma, and has remarkable clinical screening application value.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

The invention relates to the technical field of biological medicine, in particular to a cell culture medium and a preparation method of gamma delta T cells. The cell culture medium is a culture medium A or a culture medium B. The culture medium A comprises a serum-free culture medium, 1-100 [mu] M of zoledronic acid, 50-500 U / mL of IL-2, 1-5 [mu] M of imiquimod, 1-20 ng / mL of IL-15, 1-50 ng / mL of IL-1b, 10-100 ng / mL of IL-7 and 2-10% (v / v) of inactivated plasma or a serum substitute. The culture medium B comprises a serum-free culture medium, 100 to 2000 U / mL of IL-2, 1 to 50 ng / mL of IL-15, 1 to 10 [mu] M of zoledronic acid and 2 to 10% (v / v) of inactivated plasma or a serum substitute. By adopting the cell culture medium, a large number of gamma delta T cells can be rapidly obtained.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention relates to the field of plasma separation and detection, in particular to a composition for separating plasma and a using method thereof. The composition comprises: a phase change component, which is selected from n-alkanes, which are selected from at least one of n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, n-heneicosane or n-docosane; a liquid phase carrier component, wherein the liquid phase carrier component is selected from silicone oil; the structural framework and rheology regulation and control component comprises fumed silica, and the structural framework and rheology regulation and control component comprises fumed silica; the dispersion and stabilization auxiliary agent component is selected from at least one of TiO2 and BaSO4, the density adjusting filler component is selected from at least one of TiO2 and BaSO4, and the dispersion and stabilization auxiliary agent component comprises a silane coupling agent. According to the device, plasma and blood cells can be reliably, rapidly and effectively separated only through one-time low-temperature centrifugation, and remixing caused by transportation jolting can be avoided.

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

The current application reveals a method, apparatus, device, and storage medium for detecting micro residual lesions, falling within the domain of medical detection technology. This method is based on differentiated deep whole-exome / targeted drug sequencing and tissue-blood cell-plasma co-capture technology, and 100,000× ultra-high depth personalized / high evidence hotspot combination panel sequencing to evaluate tiny residual lesions and tumor evolution / second primary in plasma samples. It resolves the challenges of existing techniques, such as elevated tissue detection thresholds, restricted tracking locations, inadequate detection sensitivity and precision, or elevated costs when ctDNA concentrations in the bloodstream are minimal. Furthermore, it surmounts the challenge of simultaneously achieving personalized tracking detection and monitoring tumor evolution or second / primary detection. It markedly boosts the precision of forecasting the likelihood of recurrence following patient therapy within a restricted budget.

The present invention provides a method of removing microplastics from blood or body of a subject, including one or more tissues of the subject, by extracorporeal blood purification, including by plasma exchange, such as double filtration plasma exchange. The present invention also provides a method of treating medical conditions and methods of improving healthy lifespan and lifespan using extracorporeal blood purification, including plasma exchange, such as double filtration plasma exchange, such as by filtering microplastics from blood, and removing microplastics from a tissue or body of a subject, such as a human subject.

The invention discloses a high-specificity minimal residual disease (MRD) monitoring method and system based on circulating tumor DNA (ctDNA). The method comprises the following steps: receiving tumor tissue sequencing data of an UTUC patient, and generating a double-Panel target list containing personalized and fixed Panel; respectively extracting plasma cfDNA and leukocyte gDNA; performing vacuum concentration, hybrid capture and sequencing on the cfDNA library by using the double Panel lists, and performing deep sequencing on the leukocyte gDNA; constructing an individualized clonal hematopoietic mutation filtering database; actively filtering and rejecting clonal hematopoietic background mutation by utilizing a filtering database; and calculating an MRD load score based on the filtered tumor-derived mutation and outputting a report. The system comprises corresponding modules which are used for automatically executing the process. According to the invention, through cooperation of four major technologies of double-Panel design, process optimization, UMI error correction and active clonal hematopoietic filtration, MRD monitoring with extremely high sensitivity and specificity on UTUC is realized, false positive is significantly reduced, and the kit has drug resistance early warning potential.

The invention provides a functional nanofiber material as well as a preparation method and application thereof, and the preparation method comprises the following steps: (1) adding raw materials into water to form an electrostatic spinning solution; performing electrostatic spinning to obtain a nanofiber membrane; (2) cross-linking the nanofiber membrane in an organic solvent under the catalysis of acid to obtain a cross-linked nanofiber membrane; and (3) carrying out grafting reaction on the cross-linked nanofiber membrane in a polyamine cross-linking agent, and then reacting with a sulfur-containing reagent to obtain the functional nanofiber material, the functionalized nanofiber material prepared by the preparation method disclosed by the invention combines good biocompatibility of polyvinyl alcohol, high specific surface area and high porosity of nanofiber and a synergistic adsorption effect of the polyamine cross-linking agent and cysteine, and has the advantages of large adsorption capacity, high adsorption rate, strong selectivity, good biocompatibility, stable structure and the like; the heavy metal ions in the plasma can be efficiently and safely removed, and a plurality of defects of the existing adsorption material are overcome.

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a colorectal cancer plasma circulating microbial marker, a reagent, a kit and application thereof, and belongs to the technical field of biomedical detection. The plasma circulating microbial marker for colorectal cancer comprises alternaria alternata, alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous The colorectal cancer plasma circulating microbial marker can be used for early screening of colorectal cancer, has relatively high sensitivity and specificity, and remarkably improves the accuracy and reliability of detection; the limitation of traditional ctDNA detection is broken through, and the detection rate of early colorectal cancer is improved. The colorectal cancer plasma circulating microbial marker in a colorectal cancer plasma sample is detected through low-depth whole genome sequencing, the requirement for depth in an experiment is reduced, the cost can be greatly reduced while high sensitivity and specificity are guaranteed, and the method is more suitable for large-scale screening.

According to the screening method for the potential protein biomarkers and the drug targets of the gastric cancer, Mendel randomization analysis in a proteome range is adopted, the genetic causal relationship between circulating plasma protein and the risk of the gastric cancer is evaluated, and finally the remarkably related protein is identified. According to the screening method of the potential protein biomarker and the drug target of the gastric cancer, provided by the invention, the potential association between circulating plasma protein and the gastric cancer is systematically revealed by integrating Mendel randomization, single-cell RNA sequencing analysis, space transcriptome analysis, virtual drug screening, molecular docking, molecular dynamics simulation and other methods.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention relates to the technical field of medicines. The invention particularly relates to a heterocyclic compound, a pharmaceutical salt and a pharmaceutical composition thereof, which can be used for reducing the concentration of plasma Lp (a).

Fluid analyzation devices, methods, and systems are disclosed including an analyzation device comprising a sample vessel having an outer surface, a microchannel within the confines of the outer surface, a first port extending through the outer surface to the microchannel, and a second port extending through the outer surface to the microchannel; and an piezo transducer bonded to the outer surface of the sample vessel to form a monolithic structure, the piezo transducer configured to emit ultrasonic acoustic waves having a first frequency, a second frequency, and a third frequency into and / or to a blood sample within the microchannel, the first frequency configured to begin separation of red blood cells and plasma in the blood sample, the second frequency configured to complete separation of the red blood cells and plasma, and the third frequency configured to rupture cell walls of the blood cells producing a lysed blood sample.

To provide a method and device for predicting plasma concentration transition in combination of multiple drugs, by easily determining Ki, fm in vivo, and making them into a database, since, there has been dynamic prediction using a physiologic medicine speed theory (PBPK) model, as a prediction method of a drug interaction for medical products, however, prediction using an inhibition constant (Ki) of in vitro data and a contribution ratio (fm) of a metabolic enzyme, do not always match increase of clinical AUC.SOLUTION: There is provided a method for determining a parameter of a compartment model from a pharmacokinetic parameter of an interacted drug and interaction drug, then converting the compartment parameter into a PBPK model parameter, then determining by simulation using the PBPK model, a Ki value and fm being AUC increase ratios observed clinically. The acquired parameter is made into a database, and simulation of blood concentration transition of the interacted drug and interaction drug is performed.SELECTED DRAWING: Figure 1

The invention discloses a high-purity P-PRP preparation system and a preparation method thereof. The high-purity P-PRP preparation system comprises a sterile syringe for sampling, a centrifugal machine for providing a centrifugal effect, a centrifugal sleeve and a separator for purifying a sample of the centrifuged sterile syringe, the centrifugal sleeves are of two types and comprise an inverted centrifugal sleeve used for first-time centrifugation and an upright centrifugal sleeve used for second-time centrifugation. The preparation method comprises the steps of sample preparation, primary centrifugation, purification and re-sampling, secondary centrifugation, final sampling and the like, and finally the leukocyte-depleted platelet-rich plasma with high purity is obtained. According to the system and the method, a conventional medical general syringe can be directly used for the closed centrifugal sleeve, the problem that the syringe makes contact with the outside in the transferring and centrifuging process is effectively solved, the pollution risk in the PRP preparation process is reduced, meanwhile, P-PRP is conveniently extracted, the influence of liquid hanging on the wall on purity is avoided, the purity is improved, and residual pollution is rejected.

The utility model discloses a leukocyte-rich PRP (platelet rich plasma) extraction device. The centrifugal tube comprises a centrifugal tube body and a tube cap which are buckled with each other, the centrifugal tube body sequentially comprises a first cavity, a second cavity and a third cavity from top to bottom, the first cavity, the second cavity and the third cavity are communicated in sequence, and the tube inner diameter of the second cavity is smaller than that of the third cavity; the piston is embedded in the third cavity in a manner of moving up and down; the separation device is arranged in the third cavity in a penetrating manner; the separation device moves in the length direction of the second cavity so as to communicate or close the second cavity and the third cavity; according to the scheme, the leukocyte-rich platelet-rich plasma (LR-PRP) extraction device is efficient and easy and convenient to operate, high-concentration platelets and leukocytes can be effectively separated and extracted in single operation, the operation steps are simplified, the pollution risk is reduced, the extraction efficiency and the sample activity are improved, and therefore clinical requirements are better met.

The invention discloses a preparation method of a CGRP detection kit and application of the CGRP detection kit in migraine diagnosis, and belongs to the technical field of biological medicine detection. According to the invention, alpha-CGRP polypeptide coupled KLH protein is subjected to efficient animal immunization, an antibody with good affinity is screened by using methods such as enzyme-linked immunosorbent assay, cross pairing analysis is carried out, and final antibody sequence information is obtained through sequencing. The paired monoclonal antibody screened by the invention has high sensitivity (KD value of 1nM), the limit of detection (LoD) can be as low as pg / mL level, a low-concentration CGRP sample can be effectively detected, the matrix effect of human serum / plasma can be effectively neutralized by an optimized sample diluent formula, and the repeatability is high (in-plate and inter-plate CV values of 1t and 10%). According to the invention, the kit prepared from the specific paired antibody is systematically and closely linked with the indication function of migraine for the first time, and a clinical diagnosis direction is provided.

The invention relates to the technical field of medical biology, and discloses an application of a biomarker in the diagnosis of ejection fraction retention type heart failure, and the biomarker is kynuric acid. The biomarker is applied to preparation of a product for diagnosing or predicting ejection fraction retention heart failure. According to the method, the ejection fraction retention heart failure can be diagnosed by quantitatively detecting the kynuric acid in the plasma.